Jose-Luis-López-Lorenzo

José Luis López Lorenzo

Hematología y Hemoterapia

Degree

MEDICINE SCHOOL. POSTGRADUATE DEGREE IN HEMATOLOGY. SPECIALIZATION IN ONCOHEMATOLOGY, HEMATOPOIETIC STEM CELL TRANSPLANTATION AND CELLULAR THERAPY

Experience

POSTGRADUATE DEGREE IN HEMATOLOGY AT HOSPITAL LA PRINCESA
HEMATOLOGIST CONSULTANT AT CLINICA RUBER, CLINICA MONCLOA, AND HOSPITAL LA PRINCESA
HEMATOLOGIST AT FUNDACION JIMENEZ DIAZ FROM 1997 TO TODAY
VOLUNTEER AT NY PRESBITERIAN HOSPITAL IN NEW YORK BETWEEN 2006 AND 2007

Research and teaching

Research:

  • Clinical investigation in leukemia, gene therapy, stem cell transplantation and celular therapy

Teaching:

  • Regular hematology lessons to medical students of UAM
  • Face-to-face and Online presentations at Hematology Department of FJD
  • Lectures and presentations at ASH, SEHH, AMHH

Awards and certifications

  • EHA Member
  • EBMT Member
  • JACIE Inspector
  • SEHH , PETHEMA and GETH-TC Member
  • Manager of "Grupo de Trasplante y Terapia celular" of AMHH

Publications

1: Pinto FR, Cascos E, Pérez-López E, Baile-González M, Martín Rodríguez C, Pascual Cascón MJ, Luque M, Esquirol A, Calvo CM, Peña-Muñóz F, Fernando IH, Oiartzabal Ormtegi I, Sáez Marín AJ, Fernández-Luis S, Domínguez-García JJ, Fernández SV, López Lorenzo JL, Girón MFS, Pinedo LG, García L, González- Rodriguez AP, Torrado T, Filaferro S, Basalobre P, López-García A, Ortí G, Jurado Chacón M, Queralt Salas M. Early cardiac events after haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide. subanalysis exploring cardiac toxicity conducted on behalf of GETH-TC. Front Immunol. 2025 May 1;16:1571678. doi: 10.3389/fimmu.2025.1571678. PMID: 40375982; PMCID: PMC12079671.
2: Jiménez-Vicente C, Esteve J, Baile-González M, Pérez-López E, Martin Calvo C, Aparicio C, Oiartzabal Ormategi I, Esquirol A, Peña-Muñoz F, Fernández-Luis S, Heras Fernando I, González-Rodríguez AP, López-García A, López-Lorenzo JL, Torrado T, Sáez Marín AJ, Acosta Fleytas C, García L, Villar S, Filaferro S, Balsalobre P, Pascual Cascón MJ, Salas MQ. Allo-HCT refined ELN 2022 risk classification: validation of the Adverse-Plus risk group in AML patients undergoing allogeneic hematopoietic cell transplantation within the Spanish Group for Hematopoietic Cell Transplantation (GETH-TC). Blood Cancer J. 2025 Mar 21;15(1):42. doi: 10.1038/s41408-025-01223-x. PMID: 40118819; PMCID: PMC11928450.
3: Lloret-Madrid P, Boluda B, Martínez-López J, Bergua J, Rodriguez Arboli E, Labrador J, Sossa C, Gil C, Algarra L, Lavilla-Rubira E, Serrano J, de Rueda B, Ibañez F, González González BJ, Amigo ML, García Belmonte D, Rodríguez-Medina C, Gómez-Roncero MI, Colorado M, López Lorenzo JL, Tormo M, Arce Fernández O, Cano- Ferri I, Solana-Altabella A, Foncillas MA, Alfonso Pierola A, Vives S, Núñez MV, López-Vidal H, Pérez-Santaolalla E, Hermosín Ramos L, García Boyero R, Llorente González L, Roldán A, Calderón SC, Infante JB, Olave T, García-Suárez J, de Laiglesia A, Rodríguez-Veiga R, Trigo F, Martínez-Cuadrón D, Montesinos P. Treatment patterns and outcomes in secondary acute myeloid leukemia arising after hypomethylating agents: PETHEMA registry study. Cancer. 2025 Jan 1;131(1):e35696. doi: 10.1002/cncr.35696. PMID: 39748608.
4: Lahera A, Vela-Martín L, Fernández-Navarro P, Llamas P, López-Lorenzo JL, Cornago J, Santos J, Fernández-Piqueras J, Villa-Morales M. PIM1 is a potential therapeutic target for the leukemogenic effects mediated by JAK/STAT pathway mutations in T-ALL/LBL. NPJ Precis Oncol. 2024 Jul 20;8(1):152. doi: 10.1038/s41698-024-00638-2. PMID: 39033228; PMCID: PMC11271448.
5: Suárez EU, Boluda B, Lavilla E, Tormo M, Botella C, Gil C, Vives S, Rodríguez C, Serrano J, Sayas MJ, Martínez-Sánchez P, Ramos F, Bernal T, Algarra L, Bergua-Burgues JM, Pérez-Simón JA, Herrera P, Barrios M, Noriega-Concepción V, Raposo-Puglia JA, Ayala R, Barragán E, Martínez-Cuadrón D, Amigo ML, López- Lorenzo JL, Lázaro-García A, Guimaraes JE, Colorado M, García-Boyero R, De Rueda-Ciller B, Foncillas-García M, Hong A, Labrador J, Alonso-Dominguez JM, Montesinos P; PETHEMA group. Do NPM1 and FLT3-ITD mutations modify prognosis in patients treated with non-intensive regimens? Ann Hematol. 2024 Aug;103(8):2845-2851. doi: 10.1007/s00277-024-05840-7. Epub 2024 Jun 17. PMID: 38884787.


Communications and Presentations

  • "LXV Congreso Nacional de la Sociedad Española de Hematología y Hemoterapia - XXXIX Congreso Nacional de la Sociedad Española de Trombosis y Hemostasia – III Congreso Iberoamericano de Hematología", celebrado en Sevilla del 26 al 28 de octubre, participa: TERAPIAS GÉNICAS EN ANEMIAS CONGÉNITAS, se celebrará el Sábado, 28 de octubre, a las 11:00 - 12:30 h.
  • Conclusiones 63th postASH Annual Meeting and Exposition . Leucemia Aguda Mieloblastica. 28 y 29 de Enero de 2022.
  • 5º Curso de trasplante hematopoyético y terapia celular para residentes y adjuntos jóvenes del GMTH. 1 Febrero 2023. Coordinadores : Dra Irene Sanchez Vadillo. Dr Jose Luis Lopez Lorenzo. Dr Jose M Sanchez Pina.

Center

Hospital Universitario Fundación Jiménez Díaz

Insurers with whom you work

  • AEGON
  • ADESLAS
  • AGRUPACION ANFI
  • ASISA
  • AXA SEGUROS GENERALES
  • CATALANA OCCIDENTE
  • CASER
  • CIGNA
  • DIVINA PASTORA
  • DKV
  • GENERALI
  • HERMANDAD NACIONAL DE ARQUITECTOS (HNA)
  • MAPFRE
  • MUSA
  • UNIÓN MADRILEÑA
  • PRIVADOS